The significance of Epstein—Barr virus seropositivity in multiple sclerosis patients?
The significance of Epstein—Barr virus seropositivity in multiple sclerosis patients?
复制标题
爱泼斯坦-巴尔病毒血清阳性对多发性硬化症患者有何意义？
DOI：
--
复制
发表时间：
1998
影响因子：
3.5
通讯作者：
S. Haahr
中科院分区：
文献类型：
--
作者：
M. Munch;K. Riisom;T. Christensen;A. Møller;S. Haahr
本研究的目的是评估和研究先前在多发性硬化症(MS)患者中发现的EB病毒(EBV)100%血清阳性与健康对照的意义。使用一种商品化的EBV感染区分为既往感染、原发感染、复活感染和未感染的ELISAT检测(Biotest)，我们发现138例MS患者中有137例血清阳性，138例健康对照中124例血清阳性。在12 4例EB病毒阳性的健康对照组中，有4例发生原发感染，而在MS EBV阳性组中无一例发生原发感染(P=0.049652，FISHER精确检验)。这可能提示MS患者缺乏原发感染，从而强化了MS患者在发生MS之前就感染了EBV的想法，进一步的研究正在进行中，以分析EBV感染是否是这种疾病发展的先决条件。
The objective of this study was to evaluate and investigate the significance of the previously found 100% seropositivity toward Epstein–Barr virus (EBV) found in multiple sclerosis (MS) patients in contrast to healthy controls. Using a commercially available ELISA‐test (Biotest), which differentiates infections with EBV into previous infections, primary infections, reactivated infections and no previous infection, we found 137 of 138 MS patients and 124 of 138 healthy controls seropositive. A primary infection in 4 of the 124 EBV seropositive healthy controls in contrast to no primary infections in the MS EBV seropositive group was significant (P=0.049652, Fishers exact test). This may be suggestive of a lack of primary infections in MS patients, and thus strengthens the idea that MS patients are infected with EBV before development of MS. Further studies are in progress to analyse whether EBV infection is a prerequisite for the development of this disease.